K
Katyayani Tatiparti
Researcher at Eugene Applebaum College of Pharmacy and Health Sciences
Publications - 20
Citations - 1861
Katyayani Tatiparti is an academic researcher from Eugene Applebaum College of Pharmacy and Health Sciences. The author has contributed to research in topics: Tumor hypoxia & Drug delivery. The author has an hindex of 8, co-authored 19 publications receiving 1231 citations. Previous affiliations of Katyayani Tatiparti include Wayne State University.
Papers
More filters
Journal ArticleDOI
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.
Hashem O. Alsaab,Hashem O. Alsaab,Samaresh Sau,Rami Alzhrani,Rami Alzhrani,Katyayani Tatiparti,Ketki Bhise,Sushil K. Kashaw,Sushil K. Kashaw,Arun K. Iyer,Arun K. Iyer +10 more
TL;DR: The current landscape of the PD-1/PD-L1 mechanistic role in tumor immune evasion and therapeutic outcome for cancer treatment is reviewed and the current progress in clinical trials, combination of drug therapy with immunotherapy, safety, and future of check point inhibitors for multiple types of cancer are reviewed.
Journal ArticleDOI
siRNA Delivery Strategies: A Comprehensive Review of Recent Developments.
Katyayani Tatiparti,Samaresh Sau,Sushil K. Kashaw,Sushil K. Kashaw,Arun K. Iyer,Arun K. Iyer +5 more
TL;DR: This review presents a comprehensive update on the challenges of siRNA delivery and the current strategies used to develop nanoparticulate delivery systems.
Journal ArticleDOI
Advances in antibody-drug conjugates: A new era of targeted cancer therapy.
Samaresh Sau,Hashem O. Alsaab,Sushil K. Kashaw,Katyayani Tatiparti,Arun K. Iyer,Arun K. Iyer +5 more
TL;DR: With advances in bioengineering, linker chemistry, and potent cytotoxic payload, ADC technology has become a more powerful tool for targeted cancer therapy and ADCs with improved safety using humanized Abs with a unified 'drug:antibody ratio' (DAR) have been achieved.
Journal ArticleDOI
Paclitaxel and di-fluorinated curcumin loaded in albumin nanoparticles for targeted synergistic combination therapy of ovarian and cervical cancers.
Kaustubh A. Gawde,Samaresh Sau,Katyayani Tatiparti,Sushil K. Kashaw,Mohammad Mehrmohammadi,Asfar S. Azmi,Arun K. Iyer,Arun K. Iyer +7 more
TL;DR: Preliminary studies show a promising nanomedicine platform for combination therapy for leading gynecological tumor, such as ovarian and cervical cancer.
Journal ArticleDOI
Recent advances in nano delivery systems for blood-brain barrier (BBB) penetration and targeting of brain tumors.
TL;DR: In this paper, a short review attempts to clarify the challenges for delivery systems designed to cross the BBB, and provides a brief description of the different types of targeted nanodelivery system that have shown potential for success in delivering drugs to the brain.